The ATTEMPTS delivery systems for macromolecular drugs

Area of Science:

• Biotechnology
• Drug Delivery Systems
• Molecular Biology

Background:

• Targeted drug delivery aims to enhance therapeutic efficacy and minimize systemic toxicity.
• Heparin/protamine-based systems have been explored for protease drug delivery, like tissue-specific plasminogen activator (t-PA).
• Previous work proposed the Antibody Targeted, Triggered, Electrically Modified Prodrug-type Strategy (ATTEMPTS) for inactive drug delivery and triggered release.

Purpose of the Study:

• To develop a versatile drug delivery system with targeting, prodrug, and triggered activation capabilities.
• To adapt the ATTEMPTS strategy for tumor targeting using protein transduction domain (PTD) peptides.
• To demonstrate the efficacy of PTD-mediated delivery for intracellular drug transfer.

Main Methods:

• Incorporation of protein transduction domain (PTD) peptides, such as TAT, into the ATTEMPTS construct for tumor targeting.
• Conjugation of cytotoxic macromolecular drugs (e.g., TAT-gelonin, TAT-asparaginase) for in vitro and in vivo studies.
• Evaluation of the on/off regulation of PTD membrane translocation activity at tumor sites.

Main Results:

• Successful adaptation of the ATTEMPTS system for tumor targeting using PTD peptides.
• Demonstrated on/off regulation of PTD membrane translocation activity at the tumor target.
• Effective intracellular delivery of cytotoxic macromolecular drugs via PTD-mediated transport.

Conclusions:

• The PTD-mediated delivery system, derived from the ATTEMPTS approach, integrates targeting, prodrug features, release mechanisms, and cell entry.
• This system offers a generic platform for the delivery of macromolecular drugs.
• The developed system holds potential for reducing systemic toxicity in targeted therapies.